Brain Imaging Findings Predict Blood Pressure Response to Pharmacological Treatment

J. Richard Jennings, Matthew F. Muldoon, Ellen M. Whyte, Joelle Scanlon, Julie Price, Carolyn C. Meltzer

Abstract—Hypertension appears to alter brain morphology, as well as the cerebrovascular support for information processing. Because these effects might reflect progressive effects of essential hypertension on the brain, we asked whether structural and functional brain indices would predict the success of pharmacological treatment of hypertension among 45 previously unmedicated individuals. After initial structural MRI and functional positron emission tomography imaging, subjects were randomly assigned in a double-blind fashion for treatment for 1 year with either lisinopril or atenolol. Systolic and diastolic blood pressure decreases after treatment stabilization were correlated to a pretreatment index of brain aging (combined ratings of ventricle and sulcal size and white matter hyperintensities) and the pretreatment change in regional cerebral blood flow during working memory in the thalamus and posterior parietal regions of interest. In multiple regression analyses, the structural brain index and the blood flow response in the thalamus predicted 20% of the variance in the systolic blood pressure response to treatment controlling for pretreatment blood pressure, age, gender, and type and dose of medication. Alcohol use influenced the thalamic response measure, but covariates did not alter the relation between greater indices of brain aging and less successful blood pressure response to treatment. The state of the brain may be an important factor in the remediation of blood pressure. (Hypertension. 2008;52:1113-1119.)

Key Words: hypertension ■ MRI ■ positron emission imaging ■ atenolol ■ lisinopril ■ cerebral blood flow ■ blood pressure treatment

Although characteristics placing a person at risk for essential hypertension are well known, predictors of blood pressure (BP) response to pharmacological treatment, other than current BP, have received less attention.1,2 Once hypertension management has begun, appropriate clinical management and compliance with the medical regimen are clearly factors in treatment outcome.3 In addition, different treatment approaches may be more effective with, eg, diastolic hypertension versus isolated systolic hypertension; but clear clinical evidence for this has yet to be established.4 Cerebrovascular factors are rarely considered as central to disease diagnosis or treatment but are considered only if frank cerebrovascular disease co-occurs with hypertension.5 Increasing evidence of central nervous system involvement as either a cause or consequence of essential hypertension,6-12 however, led us to ask whether brain morphological indices of brain aging or regional cerebral blood flow responsivity would predict BP decline during pharmacological treatment of essential hypertension.

A number of factors suggest that cerebral structure and function might relate to success of BP treatment. First, hypertension has been characterized as accelerated aging, and aging changes in the brain are well established.13-16 Second, hypertension has been related to changes in both brain structure and cerebrovascular responsivity during information processing.6,9,17-19 Third, hypertension in mid-to-late life is associated with mild cognitive deficits.7,11,20 These observations, which distinguish hypertensive patients from similarly aged normotensive individuals, suggest that the brain is a target organ for essential hypertension. The impact of the disease on the brain may also interact with treatment efficacy.21 Treatment-induced reductions in BP require adaptation of central nervous system blood flow regulation, an adjustment that may be more efficient in a “younger” brain.22 Indirect evidence for this suggestion is difficulty in controlling hypertension in the elderly, the increasing use of multiple drugs, and the high prevalence of difficult-to-control hypertension.23-25 Taken together, brain indices were hypothesized to predict the degree of success of BP lowering, because the state of the brain may indicate both severity and progression of hypertensive disease and capacity for return to normal regulation of blood flow and pressure.

Based on this rationale, we examined the success of pharmacological treatment of BP as a function of brain
structure and responsivity. Relevant results were available from a project comparing the effects of an angiotensin-converting enzyme inhibitor and a \( \beta \)-blocker on regional cerebral blood flow (CBF; rCBF).

We used structural indices of brain aging (sulcal and ventricular size, as well as white matter hyperintensities) and used a measure of functional cerebrovascular responsivity, the rCBF response to information processing in 2 areas previously shown sensitive to both aging and hypertension, the posterior parietal cortex and thalamus.\(^9,27–29\) Responsivity was examined, because overall CBF does not seem altered by hypertension in midlife samples.\(^9,18\) In sum, using data collected in a 1-year clinical trial involving 45 hypertensive individuals, we tested the hypothesis that magnetic resonance (MRI)–derived indices of brain aging and positron emission tomography (PET) indices of functional response to working memory predict the magnitude of BP lowering with standard pharmacological treatment.

### Methods

**Participants**

Participants were a community sample recruited from the Pittsburgh area via radio, television, newspaper, and health fairs. Participants were between 35 and 65 years of age and had an average diastolic (fifth phase) BP of 90 to 109 mm Hg, systolic BP of 140 to 179 mm Hg, or both. Nonelderly individuals with mild-to-moderate hypertension were selected to enhance the likelihood that treatment would facilitate the reversibility of any cerebrovascular dysfunction. Seated BP was assessed after \( \geq 5 \) minutes of rest using the auscultatory technique with a mercury manometer. Baseline BP was calculated from the average of the last 2 of 3 readings done on 2 occasions. Participants were required to have either no previous pharmacological treatment for hypertension or \( \leq 6 \) months of BP medication within the past 5 years, with no BP medication taken in the 6 months preceding enrollment. Detailed inclusion/exclusion criteria for this study have been presented previously.\(^26\) Screening was designed to exclude secondary hypertension, use of drugs/substances interfering with accurate and safe treatment/assessment, and the presence of other serious disease, notably coronary or cerebrovascular disease. The University of Pittsburgh Institutional Review Board approved all of the procedures as consistent with ethical principles, and subjects provided informed consent.

**Design**

Initial BP assessment, medical screening and history, physical examination, administration of self-report questionnaires, and detailed consent followed telephone screening. The next session included the second BP assessment and neuropsychological examination. Separate sessions followed for brachial artery ultrasound, MRI, and PET examinations. All of the examinations were repeated after 1 year, except for the screening and self-report instruments. Details of psychological and neuropsychological testing and results will be presented elsewhere. This report focused on 43 of the 45 participants who completed the entire study. Participants were similar to noncompleting individuals in age, education, and personality factors; they differed in that continuing participants were significantly \( \chi^2 P<0.05 \) more likely to be male, white, and married.

**Medication Procedures**

Patients were treated for 1 year within a randomized, double-blind design using either lisinopril or atenolol, a choice of drugs based on the initial hypothesis that lisinopril would alter brain function more than atenolol.\(^5\) Medications were contained in unembossed capsules to ensure blinding. During a 6-week titration phase, drug dosage was gradually increased across 4 dosage levels: 10, 20, 30, and 40 mg for lisinopril and 25, 50, 75, and 100 mg for atenolol. During this phase, participants were seen every 2 weeks for dosage adjustment and determination of BP, compliance, and adverse effects. Upward titration stopped if a participant’s BP had fallen to \( \leq 135/85 \) mm Hg or if resting pulse fell to \( \leq 50 \) bpm. If a participant’s BP remained \( >140/90 \) mm Hg on the full-dose treatment, 12.5 mg of hydrochlorothiazide was added (4 in lisinopril group and 7 in \( \beta \)-blocker group). Participants were withdrawn from the study if BP averaged \( >160/95 \) mm Hg on 2 consecutive visits during the maintenance phase (week 6 through the final visit at week 52). During visits, physical symptoms and impact of hypertension on quality of life were assessed with the Bulpitt Hypertension Questionnaire,\(^30,31\) and adherence was estimated based on returned pill counts. The BP treatment effect was calculated from standardized BP assessment performed during the last regular clinical visit (approximately week 40). Estimates from final readings during the PET session (week 52) were deemed unrepresentative given the stress of that session.

### Structural MRI Measures

All of the subjects underwent a structural MRI using a GE Sigma 1.5 T scanner to provide a detailed image for mapping PET results and for assessment of white matter hyperintensities. A brief scout T1-weighted image was followed by an axial series oriented to the plane along anterior and posterior commissures: fast spin echo T2-weighted (effective echo time/repetition time: 102/2500 milliseconds, 1 excitation), proton density–weighted (effective echo time/repetition time: 17/2000 milliseconds, 1 excitation), and fast fluid-attenuated inversion recovery (FLAIR; effective echo time/repetition time: 56/9002 milliseconds, time to inversion: 2200 milliseconds, 1 excitation).\(^9\) Section thickness was \( 5 \) mm with a 1-mm intersection gap. A field of view of 24 cm and image matrix of 256\( \times \)192 pixels were used for all of the axial magnetic resonance series. A volumetric spoiled gradient-recalled sequence with parameters optimized for maximal contrast among gray matter, white matter, and spinal fluid was acquired for purposes of region of interest (ROI) placement in the coronal plane (echo time/repetition time: 5/25 milliseconds, flip angle 40°, 1 excitation, section thickness 1.5 mm, 0-mm intersection). Severity of white matter hyperintensities, ventricle size, and sulcal size were graded using a 10-point scale (range of these summary indices: 0 to 93% and for FLAIR images was 94%). Participants showing evidence of significant lacunar or other infarcts \((n=2)\) were excluded from participation. These were identified from the MRI films by a board-certified neuroradiologist. Significant infarcts were those judged to potentially influence functional images and/or to influence cognitive processing.

Two summary measures of brain aging were created. Based on ratings of T2/T1/proton measures, we combined ventricle size, sulcal size, and white matter load (correlations between individual scores and index, \( r=0.69 \) to 0.84). Based on the FLAIR images, we combined overall brain ratings of ventricle size, of sulcal size, of periventricular white matter load, and of subcortical white matter load (correlations between individual scores and index, \( r=0.67 \) to 0.86). Ratings were scaled identically (0 to 9), so ratings from each category were simply added together (combined with equal weighting). Because of technical issues, 1 fewer patient had FLAIR indices available relative to the T2/T1 index. We only present FLAIR-based rating data, however, because this modality has greater specificity for white matter abnormalities. Both summary indices, however, related very similarly to BP results.

### Functional PET Measures

Four quantitative (arterial sampling) PET scans were performed that tested rCBF responses during information processing (working memory tasks). Two scans examined a control state and 2 the active memory state; task order was randomized. Each task used the same display and 2 button responses. The control memory task required the subject to respond with the thumb to any letter appearing on the left of the screen and with the index finger for a letter appearing on the right. The 2-back memory task required the subject to respond very similarly to BP results.
with the thumb if spatial position of the letter currently appearing matched the spatial position, which appeared 2 times back, and the
index finger if it did not. Each task lasted 5 minutes and started 2
minutes before tracer injection. An intertask interval of ~5 minutes
rested the subject and permitted time for preparation and delivery of
the tracer. See our previous article for further description.36 PET
scans were acquired, in 3D imaging mode, using a Siemens/CTI
ECAT HR+PET scanner (63 transaxial planes, 2.4-mm section
thickness). PET data were corrected for radioactive decay, photon
attenuation, and scatter.34 Data were reconstructed using filtered
backprojection. The final image resolution was ~6 mm (transverse
and axial). Head motion was minimized using a thermoplastic mask.
A peripheral vein catheter was inserted for tracer injections and a
radial artery catheter for arterial blood sampling. An initial 10-
minute transmission scan was performed using rotating 68Ge/68Ga
rods (attenuation correction). Nine millicuries of $[^{15}O]$water were
injected as a rapid bolus using an automated injector system. A
180-second emission scan was acquired in 20 sequential frames
(10×3 seconds, 3×10 seconds, 4×15 seconds, and 3×20 seconds),
followed by a 5-minute rest period for a total of 8 minutes between
injections. Through calibration measurements, both blood and PET
brain time-activity data were converted to microcuries per milliliter.
All of the PET images were corrected for small head movements
using Automated Image Registration,36 which was also used in a
modified form to align and center the PET data.36

Quantitative CBF
The $[^{15}O]$water data were analyzed using a 1-tissue compartment
model.37,38 Model parameters corresponded with the clearance of
water from blood to brain (K1; mL/min per milliliter), brain-to-blood
transfer (k2; min⁻¹), and an arterial input function timing delay (3t).
The 3 parameters were simultaneously determined using an iterative
least-squares curve fitting on a regional basis. K1 is a clearance
parameter that is directly proportional to flow, and K2 was used as a
blood flow measure (mL/min per milliliter).

ROIs were defined based on areas of activation that differed between
patients and normotensive controls in a previous/separate study.9 The ROIs were regionally defined on the spoiled gradient-
recalled MRI for each participant and manually drawn using a
version of the Imagentool software (CTI PET Systems). ROI place-
ment is illustrated in a previous online supplement.26 For current
purposes, we examined the response to 2-back memory relative to
control in the thalamic and posterior parietal ROIs, because these
differed between hypertensive patients and controls in our previous
work.9

Analysis
We tested the hypothesis that the brain aging index and rCBF
response to working memory in thalamic or posterior parietal ROIs
would predict treatment outcome using ordinary least-squares mul-
tiple regression (StatSoft, Inc). A hierarchical regression analysis
was performed. In step 1 (basic model), age, drug assignment
(lisinopril versus atenolol), and pretreatment systolic BP were used
to predict change in systolic BP with treatment. Step 2 added
variables to see whether they further explained variance in treatment
response after adjustment for the basic model. Separate step 2
models were tested for parietal response during working memory,
thalamic response during working memory, and brain aging index.

Brain factors that significantly improved on the variance explained
by the basic model were then entered together in a separate step 2
model to provide an estimate of overall prediction of BP treatment
success using brain indices. Finally, covariates (see Table 1) were
added to this model to see whether they altered the predictivity of
brain factors. A covariate for dosage levels was used with a score
corresponding to the dose level achieved at the end of treatment (1
to 4 for lisinopril or atenolol dose level and a 5 if hydrochlorothia-
zide was added). Because of the relatively small sample size,
covariates were not added concurrently. The same analytic approach
was repeated with diastolic BP and pulse pressure change during
treatment as the dependent variable.

Results

Participant Characteristics
Figure 1 diagrams selection and retention characteristics of the
sample. Medication was well tolerated, but a substantial
number of patients were excluded after initial consent be-
because of our medical exclusions (see above) and because of
their loss of interest before treatment but after further con-
sideration of the demands of the study.

Table 1 provides details of subject characteristics. To provide
evidence of the variability in treatment response and to allow examina-
tion of factors related to treatment response, the sample was divided by median systolic BP response. Most
baseline characteristics and medication type (lisinopril or atenolol) did not significantly influence BP response; how-
ever, higher initial systolic BP was associated with a greater
decrease in systolic BP with treatment.

Overall, patients showed values of white matter and rCBF
response indices comparable to previous work. Ratings from
the FLAIR images showed mean values (SEs) for ventricle
size of 2.30 (0.14), sulcal size of 2.70 (0.15), periventricular
white matter of 1.40 (0.13), and subcortical white matter of
1.50 (0.27). These values are comparable to those from our
previous study9 and appear appropriate for age in comparison
with epidemiological data.33 Similarly, values observed were
somewhat higher but comparable to ours and others for mean
rCBF in the thalamic area (63.8 [2.1] mL/min per milliliter)
and response in this area to the 2-back memory task (3.9 [0.9]
L/min per milliliter).9,39,40

Association With Treatment Response
MRI indices of brain aging, as well as the responsivity of the
thalamic ROI during PET scanning, were associated with a
subsequent degree of BP lowering with treatment. Table 2
shows the results of the hierarchical multiple regression
analyses. Step 1 in the analysis tested a basic model that
included age, medication type, and initial BP (factors typi-
cally assumed to alter treatment response). The table shows
the standardized β weights for the predictors as related to the
change in BP in millimeters of mercury. For example,
pretreatment BP shows a negative β weight, indicating that
the higher initial pressure was related to a greater decrease in
BP with treatment. Step 2 analyses then asked if further
variance in treatment outcome could be explained by brain
variables. Step 2a added the brain aging index. Step 2b added
only the responsivity in the thalamic ROI. Step 2c added the
brain aging index and the thalamic responsivity concurrently.

The increment in variance explained associated with each
variable in the model is shown in Table 2. Addition of
the parietal ROI is not shown, because responsivity in this
area failed to relate to BP treatment response. Note that the
“n” with different analyses differs somewhat, eg, the “n” for
the PET response is decreased because of refusal of the
arterial catheter by 4 participants. The step 2c model with
both the FLAIR index and thalamic responsivity predicted
60% of the variance in SBP treatment outcome. Brain indices
added 20% to the prediction of the basic model. The regres-
sion results in Table 2 are supplemented by Figure 2, which
illustrates the basic bivariate relationship between the systolic BP treatment outcome and brain aging.

The combined model, ie, brain aging and thalamic reponsivity, together with the factors in the basic model, was further tested using diastolic BP and pulse pressure rather than systolic BP as the dependent variable. The results for diastolic BP completely paralleled the results for systolic BP shown in Table 2. Statistical significance at \( P<0.05 \) or better was consistent with the systolic BP results throughout. The combined model showed significant standardized \( \beta \)s for initial diastolic pressure (\(-0.429, t=-2.98, P<0.001\)), FLAIR aging index (\(0.374, t=2.19, P=0.03\)), and rCBF change in the thalamic ROI (\(-0.351, t=2.42, P=0.02\)). Results for pulse pressure remained significant only for the FLAIR

<table>
<thead>
<tr>
<th>Subject Characteristic</th>
<th>Above Median Decrease (n=22)</th>
<th>Below Median Decrease (n=21)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, y</td>
<td>53.7 (4.8)</td>
<td>51.3 (8.2)</td>
</tr>
<tr>
<td>BMI</td>
<td>29.9 (5.4)</td>
<td>30.1 (4.2)</td>
</tr>
<tr>
<td>Heart rate, bpm</td>
<td>73.0 (9.8)</td>
<td>69.5 (7.0)</td>
</tr>
<tr>
<td>Qualifying systolic, mm Hg</td>
<td>150.0 (7.2)</td>
<td>145.0 (2.9)</td>
</tr>
<tr>
<td>Qualifying diastolic, mm Hg</td>
<td>94.0 (9.6)</td>
<td>97.0 (6.6)</td>
</tr>
<tr>
<td>Gender, proportion male</td>
<td>0.68</td>
<td>0.86</td>
</tr>
<tr>
<td>Race, proportion white</td>
<td>0.90</td>
<td>0.86</td>
</tr>
<tr>
<td>Nicotine use, mean No. of cigarettes per week</td>
<td>0.09 (0.42)</td>
<td>0.43 (0.84)</td>
</tr>
<tr>
<td>Alcohol use, mean No. of drinks per week</td>
<td>2.0 (0.98)</td>
<td>2.2 (1.5)</td>
</tr>
<tr>
<td>Dosage level, low=1, high plus hydrochlorothiazide=5</td>
<td>2.8 (1.5)</td>
<td>2.1 (1.3)</td>
</tr>
<tr>
<td>Percent compliance*</td>
<td>98 (3)</td>
<td>99 (2)</td>
</tr>
<tr>
<td>SBP change in ACE-I treated, mm Hg</td>
<td>-25.0 (3.9)</td>
<td>-4.0 (10.4)†</td>
</tr>
<tr>
<td>SBP change in ( \beta )-blocker treated, mm Hg</td>
<td>-26.0 (9.3)</td>
<td>-8.0 (8.7)†</td>
</tr>
<tr>
<td>Total cholesterol, mg/dL</td>
<td>214 (34)</td>
<td>209 (33)</td>
</tr>
<tr>
<td>High-density lipoprotein, mg/dL</td>
<td>60 (43)</td>
<td>56 (31)</td>
</tr>
<tr>
<td>Low-density lipoprotein, mg/dL</td>
<td>135 (32)</td>
<td>129 (33)</td>
</tr>
<tr>
<td>Triglycerides, mg/dL</td>
<td>152 (138)</td>
<td>168 (126)</td>
</tr>
</tbody>
</table>

*Compliance was assessed by pill counts at the time of clinical visits.†Group differences were necessarily significant by definition, but no differences were found between medication groups by \( t \) test or 2-way ANOVA.

Data are mean (SE) unless otherwise specified. No significant difference \( (P<0.05) \) was found between groups by \( t \) test. No differences were statistically significant for proportions. Median posttreatment systolic BP was 123 mm Hg, with patients separated by the median change in systolic BP of \(-18 \) mm Hg. BMI indicates body mass index; SBP, systolic BP.
Jennings et al  
Brain Aging and Blood Pressure Lowering  

Table 2. Multiple Regression Results for Base Model and for Additions to the Model of Brain Aging Indices and rCBF Response to Working Memory in the Thalamic ROI

<table>
<thead>
<tr>
<th>Factor</th>
<th>$\beta$ Weight (Standardized)</th>
<th>Standard Error of $\beta$</th>
<th>t Value</th>
<th>$P$</th>
<th>$r^2$ Increment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Base model (step 1) N=43 ($r^2=0.39$)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age</td>
<td>0.240</td>
<td>0.131</td>
<td>1.84</td>
<td>0.07</td>
<td></td>
</tr>
<tr>
<td>Drug group</td>
<td>0.068</td>
<td>0.123</td>
<td>0.24</td>
<td>Ns</td>
<td></td>
</tr>
<tr>
<td>Initial systolic BP</td>
<td>-0.660</td>
<td>0.130</td>
<td>-5.09</td>
<td>&lt;0.001</td>
<td></td>
</tr>
<tr>
<td>Base model plus FLAIR aging (step 2a) N=43 ($r^2=0.50$)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FLAIR aging</td>
<td>0.428</td>
<td>0.143</td>
<td>3.00</td>
<td>0.005</td>
<td>0.11</td>
</tr>
<tr>
<td>Base model plus PET rCBF ROI response (step 2b) N=37 ($r^2=0.49$)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Thalamic ROI</td>
<td>-0.303</td>
<td>0.128</td>
<td>-2.36</td>
<td>0.02</td>
<td>0.09</td>
</tr>
<tr>
<td>Base model plus FLAIR aging and thalamic ROI (step 2c) N=37 ($r^2=0.60$)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FLAIR aging</td>
<td>0.396</td>
<td>0.137</td>
<td>2.90</td>
<td>0.007</td>
<td></td>
</tr>
<tr>
<td>Thalamic ROI</td>
<td>-0.276</td>
<td>0.116</td>
<td>-2.38</td>
<td>0.02</td>
<td>0.20</td>
</tr>
</tbody>
</table>

Greater systolic BP treatment response is scored as a more negative difference from initial systolic BP. The $r^2$ values associated with models define the proportion of variance explained by that model; those in the increment column define the change in the proportion of variance explained added by the variable(s) tabled. Base model $\beta$ weights and contributions to variance shift slightly as different variables are added. These minor changes are not presented for economy of presentation. All of the $r^2$ increments shown are statistically significant, at $P<0.05$. The parietal ROI was also added as a separate step 2 variable but was not significant ($t=-0.92$).

A substantial fraction of the variability between patients in the success of 2 standard pharmacological treatments of BP was accounted for by a combination of structural and functional indices of the brain. Structural and functional indices were independently related to treatment outcome and were also independent of the influences of chronological age, medication type, and initial BP. Furthermore, a substantial number of covariates, which potentially could have accounted for our findings, failed to alter the results (body mass index, gender, race, drug dosage level, smoking, estimated intelligence, and percent compliance). Level of alcohol use did alter the strength of the functional, but not the structural, index’s relationship to treatment outcome.

Ratings based on FLAIR images of the brain were combined to provide a general index of brain aging. This index was related to BP treatment outcomes. Scores going into the index were morphological changes in the ventricles and sulci, as well as the presence of small lesions in white matter. Subsequent checks on the contribution of these individual scores to the treatment effects showed that each score demonstrated the same direction of relationship with BP change, albeit with some variation in the strength of the relationship. The FLAIR index was recomputed without the subcortical white matter index, which was not an original scoring dimension in the Cardiovascular Health Study. Results remained essentially the same. Given this, the combined indices should provide more reliable and replicable measures than the individual scores.

Our results show poorer responses to treatment among hypertensive individuals with greater brain aging relative to their chronological age. This may imply that hypertension accelerates brain aging or that a third factor influences both hypertension and brain aging. Interestingly, accelerated aging has been postulated previously as an effect of hypertension based on physiological data unrelated to brain function or structure. Alternatively, Diz and Lewis recently reviewed results suggesting that the brain renin-angiotensin system may have parallel effects on aging and BP. Given the evidence that BP reduction can be resistant to treatment in a significant portion of cases, particularly among the elder-

Figure 2. Change in systolic BP over 40 weeks (posttreatment—pretreatment) with angiotensin-converting enzyme I or $\beta$-blocker shown as a function of pretreatment ratings of the presence of white matter lesions and ventricle and sulcal size derived from FLAIR MRIs ($r=0.30$, $n=43$).
ly,23–25 our results suggest that an aging brain may impede successful therapy.

The thalamic rCBF response to working memory tasks but not to the posterior parietal rCBF response related to the success of BP treatment, although this effect was not significant for pulse pressure or when alcohol use was controlled. Among the ROIs studied in our previous work, only the thalamic and posterior parietal showed a diminished rCBF response to working memory relative to our normotensive controls.9 Given this, we examined these 2 ROIs to see if the degree of diminished perfusion would relate to success of treatment. The thalamus shows reduced metabolic activity with aging27,45 and less gray matter volume with age in some but not all of the studies.29,46 Changes with age in thalamic activity during working memory tasks have been less consistently identified.28,47 Overall, however, the thalamus may be more susceptible to age-related, and possibly alcohol-related, changes than the posterior parietal regions. This susceptibility appears to extend to the influence of hypertension and potentially accounts for the relationship of thalamic responsiveness, but not posterior parietal responsivity, to the efficacy of BP treatment.

Except for the influence of alcohol use on the thalamic relationship just noted, neither basic demographic factors nor health -relevant factors modified the relationship between brain indices and treatment success. Compliance to treatment was uniformly high in this sample and unrelated to either BP or brain measures. There was minimal dropout after treatment was initiated. Overall, however, no covariate of our brain measures provided a convincing alternative explanation of the link between brain indices and treatment outcome.

Our interpretations are limited by our data. Our sample size and representativeness were constrained by the requirement for initially normotreated patients and the general acceptability to potential participants of imaging procedures. This limits the generalizability of our results. We did not use a placebo-treated control group for ethical and cost reasons and, thus, cannot control for the effect of time and spontaneous changes in BP. Duration of heightened BP, indices of vascular aging, and related longitudinal data were not available but would be very important for refining our interpretation. Finally, we compared only 2 common BP medications, and the results may be specific to these medications.

Overall, however, we found a surprisingly strong relationship between brain indices and the success of standard pharmacological treatment of hypertension. We do not know of any physiological mechanism that would provide a convincing, definitive explanation of how brain aging or responsiveness would influence treatment outcome. Two speculative implications may be worth noting, however. First, the pathology of essential hypertension may not solely influence BP but may have systemic effects that have suggested to many that it hastens biological aging. If so, then an early target of these processes may be the brain. A close examination of factors such as the actions of the angiotensin system in the brain and interactions with brain stem BP control areas would seem warranted based on this speculation.21 Second, the systemic reaction to BP lowering, per se, may involve adjustments in the brain. Autonomic nervous system regulation of vascular tone, sensitivity of baroreceptors, and other regulatory systems should adjust to altered pressure profiles. Such adjustment may be more effective in those with “younger,” more responsive brains. Studies throughout the course of treatment could assess whether such changes occur and whether they directly contribute to treatment success.

Perspectives

The correlation between brain indices and treatment outcome would suggest that more aggressive treatment early in the course of hypertensive disease may be beneficial for brain structure and function. At present, the expense of brain imaging precludes diagnostic use, but technical advances may permit evaluation of the use of early treatment for brain structure and function in the foreseeable future.

Acknowledgments

We thank Dr Christopher Ryan and Michelle Geckle for their assistance with the neuropsychological testing and Michael Eddy and Carl Becker for their technical assistance.

Sources of Funding

The National Heart, Lung, and Blood Institutes grant 057529 supported this research. E.M.W. was supported by a K-Award (MH067710). Assistance from the Pittsburgh Mind-Body Center (National Institutes of Health grants HL076852/076858) is also acknowledged.

Disclosures

None.

References


Brain Imaging Findings Predict Blood Pressure Response to Pharmacological Treatment
J. Richard Jennings, Matthew F. Muldoon, Ellen M. Whyte, Joelle Scanlon, Julie Price and Carolyn C. Meltzer

Hypertension. 2008;52:1113-1119; originally published online November 3, 2008;
doi: 10.1161/HYPERTENSIONAHA.108.120196
Hypertension is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2008 American Heart Association, Inc. All rights reserved.
Print ISSN: 0194-911X. Online ISSN: 1524-4563

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://hyper.ahajournals.org/content/52/6/1113

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Hypertension can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Hypertension is online at:
http://hyper.ahajournals.org//subscriptions/